FDA approves Liquidia's YUTREPIA for PAH and PH-ILD, enabling commercial launch

Liquidia Corp

FDA approved YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD to improve exercise ability.
Exclusivity for United Therapeutics' Tyvaso DPI expired May 23, 2025, clearing path for YUTREPIA final approval.
YUTREPIA uses proprietary PRINT technology for deep-lung delivery; pivotal INSPIRE study showed tolerability.
Liquidia intends to begin commercialization immediately; ongoing litigation may delay or prevent successful commercialization.
Company will host a webcast May 27, 2025 at 8:30 a.m. ET to discuss commercial launch preparations.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.